stro-001
mAbexperimentalADC
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 22, 2018 (NCT03424603)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- maytansinoid
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS0D8BWL78LD ↗
- ChEMBLCHEMBL4594500 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05611853 | Phase 1/Phase 2 (Phase 2) | Nov 25, 2022 | BioNova Pharmaceuticals (Shanghai) LTD., Henan Medical University, Huazhong University of Science and Technology, Jiao Tong University, Soochow University |
| NCT03424603 | Phase 1 | Feb 22, 2018 | Sutro Biopharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioNova Pharmaceuticals (Shanghai) LTD. | For profit | 1 | 1 | 1 | 2022 |
| Henan Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sutro Biopharma | For profit | 1 | 1 | 1 | 2018 |
6 organizations
Page 1 / 1